Evoke Pharma

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed

Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Real-world study compares diabetic gastroparesis patient utilization of healthcare resources before and after initiation of GIMOTI Real-world study compares diabetic gastroparesis patient utilization of healthcare resources before and after initiation of GIMOTI

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.”

USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued, the patent, entitled “Nasal Formulations of Metoclopramide” will expire in December 2029. This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

Evoke Pharma, Inc. (NASDAQ:EVOK ) Q3 2022 Results Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations, DKB Partners David Gonyer - President and Chief Executive Officer Chris Quesenberry - Chief Commercial Officer Matthew D'Onofrio - Executive Vice President, Chief Business Officer, Secretary and Treasurer Conference Call Participants Operator Good afternoon. And welcome to the Evoke Pharma Third Quarter 2022 Earnings Conference Call.

Evoke Pharma, Inc. (EVOK) Q3 2022 Results - Earnings Call Transcript

SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022, after the market closes.

Evoke Pharma to Report Third Quarter Results on November 9, 2022

Company will exhibit Gimoti® and meet with Key Opinion Leaders

Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting

SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 16/469,092 for GIMOTI. When granted, the patent will cover methods for treating moderate-to-severe gastroparesis with metoclopramide with an intranasal route of administration. Once issued, the patent, entitled “Treatment of Moderate and Severe Gastroparesis,” will expire in 2037. The patent will add to Evoke's existing U.S. Food and Drug Administration (FDA) Orange Book-listed patents and other patents in the EU, Japan, and Mexico.

Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI

GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies

GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award

SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company's President and CEO, David A. Gonyer, R.Ph., and Chief Business Officer, Matt D'Onofrio, MBA, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022, at the Lotte New York Palace Hotel in NYC.

Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth

Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution

Evoke Pharma, Inc. (NASDAQ:EVOK ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants David Gonyer – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer Matthew D'Onofrio – Chief Business Officer Conference Call Participants Unidentified Company Representative Good afternoon. And thank you for participating in Evoke Pharma's conference call today.

Evoke Pharma, Inc. (EVOK) CEO David Gonyer on Q2 2022 Results - Earnings Call Transcript

Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11% Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%

Evoke Pharma Reports Second Quarter 2022 Financial Results

SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its second quarter on Wednesday, August 10, 2022, after the market closes.

Evoke Pharma to Report Second Quarter Results on August 10, 2022

Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders

Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)

Rigel Pharmaceuticals

Zomedica

What to know about trading biotech stocks in 2022 The post Biotech Penny Stocks Investing Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Investing Guide

Sidus Space

Why these three penny stocks exploded during trading today The post Why These 3 Penny Stocks Exploded Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why These 3 Penny Stocks Exploded Today

Evoke Pharma (EVOK) stock is rocketing higher on Wednesday after the company got Medicaid approval for its GIMOTI nasal spray. The post Evoke Pharma (EVOK) Stock Soars 50% on Medicaid Drug Approval appeared first on InvestorPlace.

Evoke Pharma (EVOK) Stock Soars 50% on Medicaid Drug Approval

SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding GIMOTI, the Company's novel treatment solution meant to treat symptoms associated with acute and recurrent diabetic gastroparesis, to the Florida Medicaid Preferred Drug List (PDL) effective immediately.

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it received written notice from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

A 1-for-12 reverse stock split of Evoke Pharma (NASDAQ: EVOK) has gone into effect. These are the details.

Evoke Pharma (EVOK) Stock: 1-For-12 Reverse Split Goes Into Effect

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide

Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

Acasti Pharma

Guardforce AI Co Ltd

Ricebran Technologies

Penny stocks to watch under $1 today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 6 To Watch Under $1 This Week

NiSun International Enterprise Development Group Co Ltd

Penny Stocks To Buy Now? 4 To Watch Under $1 This Week

Evoke Pharma, Inc. EVOK Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants David Gonyer – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer, EVERSANA Matthew D'Onofrio – Chief Business Officer Daniel Kontoh-Boateng – Investor Relations Conference Call Participants Yale Jen – Laidlaw and Company Mitchell Kapoor – H.C. Wainwright & Co., LLC Operator Please stand by.

News for Evoke Pharma Stock (EVOK)